The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas

Cancer Control

Volumn 13, Issue 1, 2006, Pages 61-71

  Hodul, Pamela ^a   Malafa, Mokenge ^a   Choi, Junsung ^a   Kvols, Larry ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GELATIN SPONGE; INTERFERON; KI 67 ANTIGEN; LIVER ENZYME; MICROSPHERE; MITOMYCIN; OCTREOTIDE; OCTREOTIDE[3 TYROSINE]; POLYVINYL ALCOHOL; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; STREPTOZOCIN; YTTRIUM 90;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ARTIFICIAL EMBOLISM; BILE DUCT FISTULA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOSENSITIVITY; CHOLECYSTECTOMY; CHRONIC CHOLECYSTITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; FEVER; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL SYMPTOM; HEMICOLECTOMY; HEPATIC ARTERY; HISTOPATHOLOGY; HUMAN; LIVER ABSCESS; LIVER METASTASIS; LIVER RESECTION; LIVER SURGERY; LOW DRUG DOSE; MORBIDITY; MULTIMODALITY CANCER THERAPY; NEUROENDOCRINE TUMOR; PANCREAS ADENOCARCINOMA; PARTIAL HEPATECTOMY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RECURRENCE RISK; REVIEW; SCINTIGRAPHY; SURGICAL MORTALITY; SURGICAL RISK; SURVIVAL RATE; SURVIVAL TIME; SUSTAINED DRUG RELEASE; SYMPTOM; TREATMENT RESPONSE; VOMITING;

EID: 33644656922     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601300109     Document Type: Review

References (55)

1. Lubarsch O. Ueber den primaren krebs des ileum nebst bemerkungen uber das gleichzeitige vorkommen von krebs und tuberkolose. Virchow Arch Pathol Anat Physiol Klin Med. 1888;111:280-317.
2. Oberndorfer S. Uber die "kleinen Dünndarmcarcinome." Verh Dtsch Ges Pathol. 1907;11:1213-1216.
3. Oberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol. 1996;7:453-463.
4. Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315:663-666.
5. Moertel CG. Karnofsky memorial lecture: an odyssey in the land of small tumors. J Clin Oncol. 1987;5:1502-1522.
6. Thompson GB, van Heerden JA. Grant CS, et al. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery. 1988;104:1011-1017.
7. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519-523.
8. Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol. 1998;21:36-38.
9. Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol. 1983;1:727-740.
10. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials. 1979;2:327-334.
11. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169:36-43.
12. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37.
13. Chen H, Hardacre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187:88-93.
14. Nave H, Mossinger E, Feist H, et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery. 2001;129:170-175.
15. Jaeck D, Oussoultzoglou E, Bachellier P, et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg. 2001;25:689-692.
16. Norton JA, Warren RS, Kelly MG, et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057-1065.
17. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery. 1992;112:1024-1032.
18. The SSAT, AGA, ASLD, ASGE, AHPBA Consensus Panel. Treatment of hepatic metastases from colorectal cancer. J Gastrointest Surg. 1997;1:396-397.
19. Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132:505-511.
20. Que FG, Sarmiento JM, Nagorney DM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Cancer Control. 2002;9:67-79.
21. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30:969-977.
22. Charnsangavej C, Chuang V, Wallace S, et al. Angiographic classification of hepatic arterial collaterals. Radiology. 1982;144:485-494.
23. Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998;83:2293-2301.
24. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes. J Am Coll Surg. 2000;190:432-445.
25. Sutcliffe R, Maguire D, Ramage J, et al. Management of neuroendocrine liver metastases. Am J Surg. 2004;187:39-46.
26. Fiorentini G, Rossi S, Bonechi F. Intra-arterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II study. J Chemother. 2004;16:293-297.
27. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994;120:302-309.
28. Strosberg JR, Choi J, Cantor AB, et al. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006;13:72-78.
29. Ajani JA, Carrasco CH, Charnsangavej C, et al. Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med. 1988;108:340-344.
30. O'Toole D, Maire F, Ruszniewski P. Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer. 2003;10:463-468.
31. Roche A, Girish BV, de Baere T, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol. 2003;13:136-140. Epub 2002 Jul 23.
32. Ihse I, Persson B, Tibblin S. Neuroendocrine metastases of the liver. World J Surg. 1995;19:76-82.
33. Curley SA. Radiofrequency ablation of malignant liver tumors. Oncologist. 2001;6:14-23.
34. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002;26:985-990. Epub 2002 May 21.
35. Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res. 2001;95:8-12.
36. Henn AR, Levine EA, McNulty W, et al. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR Am J Roentgenol. 2003;181:1005-1010.
37. Hellman P, Ladjevardi S, Skogseid B, et al. Radiofrequency tissue ablation using cooled tip for metastases of endocrine tumors. World J Surg. 2002;26:1052-1056. Epub 2002 May 21.
38. Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastasis. World J Surg. 2001;25:693-696.
39. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227-232.
40. Oberg K, Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol. 1991;30:519-522.
41. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion. 2000;62(suppl 1):92-97.
42. Oberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer Drugs. 1994;5:503-519.
43. Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci. 1989;34:14S-27S.
44. Oberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analog octreotide. Acta Oncol. 1991;4:503-507.
45. Chung MH, Pisegna J, Spirt M, et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery. 2001;130:954-62.
46. Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer. 1997;79:830-834.
47. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966-973.
48. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):62S-66S.
49. Wong RJ, DeCosse JJ. Cytoreductive surgery. Surg Gynecol Obstet. 1990;170:276-281.
50. Sarmiento JM, Que FG, Grant CS, et al. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery. 2002;132:976-983.
51. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 1996;125:26-34.
52. Soreide O, Berstad T, Bakka A, et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumours. Surgery. 1992;111:48-54.
53. McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091-1096.
54. Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130:1078-1085.
55. Melendez JA, Arslan V, Fischer ME, et al. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg. 1998;187:620-625.